Parkinson disease (PD) is the second most common neurodegenerative disorder, affecting>
1% of the population≥ 65 years of age and with a prevalence set to double by 2030. In …

Objective Prevalence rates of anxiety disorders in Parkinson's disease (PD) vary widely,
ranging from 6% up to 55%. The aim of this systematic review was to calculate the average …

In the course of Parkinson's disease (PD), the enteric nervous system (ENS) and
parasympathetic nerves are amongst the structures earliest and most frequently affected by …

Background Several publications have described differences in cross-sectional
comparisons of gut microbiota between patients with Parkinson's disease and control …

Nonmotor symptoms (NMS) in Parkinson's disease (PD) can precede onset of motor
symptoms. Relationship between premotor symptoms onset and motor features is limited …

We conducted a systematic review and meta‐analysis aimed at establishing robust
prevalence estimates and identifying clinical correlates of fatigue in PD. From 2,459 titles …

Abstract The Movement Disorder Society (MDS) Task Force on Evidence‐Based Medicine
(EBM) Review of Treatments for Parkinson's Disease (PD) was first published in 2002 and …

Background: Non‐motor symptoms are detrimental to health‐related quality of life (HRQoL)
of Parkinson's disease patients. In this study, the Non‐Motor Symptoms Scale (NMSS) was …

Premotor and nonmotor features of Parkinson's disease : Current Opinion in Neurology
Premotor and nonmotor features of Parkinson's disease : Current Opinion in Neurology Log in or …

The clinical diagnosis of Parkinson's disease rests on the identification of the characteristics
related to dopamine deficiency that are a consequence of degeneration of the substantia …